Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Erytech Pharma ADR (ERYP)

Erytech Pharma ADR (ERYP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,614
  • Shares Outstanding, K 34,120
  • Annual Sales, $ 32,660 K
  • Annual Income, $ -240 K
  • 60-Month Beta 2.69
  • Price/Sales 0.81
  • Price/Cash Flow N/A
  • Price/Book 0.98
Trade ERYP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 04/26/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7110 +9.70%
on 06/27/23
0.9599 -18.74%
on 06/05/23
-0.0869 (-10.02%)
since 05/26/23
3-Month
0.6910 +12.88%
on 05/03/23
1.3000 -40.00%
on 05/15/23
-0.1431 (-15.50%)
since 03/28/23
52-Week
0.3000 +160.00%
on 12/23/22
1.4720 -47.01%
on 08/17/22
-0.3600 (-31.58%)
since 06/28/22

Most Recent Stories

More News
Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why

Erytech Pharma SA Sponsored ADR (ERYP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

ERYP : 0.7800 (unch)
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

HTGM and VAPO are leading our lists this morning

HTGM : 0.4800 (-20.00%)
ERYP : 0.7800 (unch)
BRK.A : 603,000.00 (-0.56%)
HPQ : 28.18 (+0.86%)
MDVL : 1.8000 (-40.59%)
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech

ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech

ERYP : 0.7800 (unch)
ERYTECH Announces the Availability of its Half-Year Financial Report 2021

ERYTECH Announces the A vailability of its H alf- Y ear F inancial R eport 202 1

ERYP : 0.7800 (unch)
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 20 2 1

ERYP : 0.7800 (unch)
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

ERYTECH t o Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

ERYP : 0.7800 (unch)
ERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

ERYTECH to Present at the H.C. Wainwright 23 rd Annual Global Investment Conference

ERYP : 0.7800 (unch)
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2021

ERYP : 0.7800 (unch)
ERYTECH to Participate in the Citi 16th Annual BioPharma Conference

ERYTECH to Participate in the Citi 16 th Annual BioPharma Conference

ERYP : 0.7800 (unch)
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

ERYP : 0.7800 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Erytech Pharma S.A. operates as a biopharmaceutical company. It discovers and developes therapies for rare forms of cancer and orphan diseases. The company's product pipeline consists of eryaspase, erymethionase, eryminase, ERYZYME and ERYMMUNE which are in clinical stages. It operates primarily in France...

See More

Key Turning Points

3rd Resistance Point 0.9467
2nd Resistance Point 0.9133
1st Resistance Point 0.8467
Last Price 0.7800
1st Support Level 0.7467
2nd Support Level 0.7133
3rd Support Level 0.6467

See More

52-Week High 1.4720
Fibonacci 61.8% 1.0243
Fibonacci 50% 0.8860
Last Price 0.7800
Fibonacci 38.2% 0.7477
52-Week Low 0.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar